Safikhani et al. reply

Nature

Volumn 540, Issue 7631, 2016, Pages E6-E8

  Safikhani, Zhaleh ^a,b   El Hachem, Nehme ^c   Smirnov, Petr ^a   Freeman, Mark ^a   Goldenberg, Anna ^d,e   Birkbak, Nicolai J ^f,g   Beck, Andrew H ^h,i   Aerts, Hugo J W L ^i,j,k   Quackenbush, John ^j,l   Haibe Kains, Benjamin ^a,b,e,m  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB; PACLITAXEL;

ASSAY; CANCER; CELLS AND CELL COMPONENTS; DATA SET; DRUG DEVELOPMENT; EXPERIMENTAL STUDY; GENE EXPRESSION; LABORATORY METHOD;

AREA UNDER THE CURVE; CANCER CELL LINE; DOSE RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENOME; IC50; LABORATORY; MEASUREMENT; MOLECULAR MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 85000916277     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20172     Document Type: Short Survey

References (11)

1. Mpindi, J. P. et al. Consistency in drug response profiling. Nature 540,http://dx.doi.org/10.1038/nature20171 (2016).
2. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature504, 389-393 (2013).
3. Garnett, M. J. et al. Systematic identification of genomic markers of drugsensitivity in cancer cells. Nature 483, 570-575 (2012).
4. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictivemodelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
5. Pemovska, T. et al. Individualized systems medicine strategy to tailortreatments for patients with chemorefractory acute myeloid leukemia. CancerDiscov. 3, 1416-1429 (2013).
6. Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell linepanels. Nature 533, 333-337 (2016).
7. Pozdeyev, N. et al. Integrating heterogeneous drug sensitivity data from cancerpharmacogenomic studies. Oncotarget http://dx.doi.org/10.18632/oncotarget.10010 (2016).
8. Bouhaddou, M. et al. Drug response consistency in CCLE and CGP. Nature 540,http://dx.doi.org/10.1038/nature20580 (2016).
9. Smirnov, P. et al. PharmacoGx: an R package for analysis of largepharmacogenomic datasets. Bioinformatics 32, 1244-1246 (2016).
10. Safikhani, Z. et al. Revisiting inconsistency in large pharmacogenomicstudies. F1000Research http://dx.doi.org/10.12688/f1000research.9611.1(2016).
11. Sandve, G. K., Nekrutenko, A., Taylor, J. & Hovig, E. Ten simple rules forreproducible computational research. PLoS Comput. Biol. 9, e1003285 (2013).